Literature DB >> 23335104

Metastatic gastric cancer treatment: a little slow but worthy progress.

Ozkan Kanat1, Bert H O'Neil.   

Abstract

Metastatic gastric cancer is incurable and remains one of the leading causes of cancer-related deaths around the world. Despite the significant progress in its systemic treatment, metastatic gastric cancer is still a major therapeutic challenge for oncologists. Newer chemotherapy regimens and the addition of molecularly targeted agents to chemotherapy seem to provide better clinical outcomes for patients with metastatic gastric cancer. The objective of this article is to review the current treatment approach for this formidable disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23335104     DOI： 10.1007/s12032-013-0464-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  88 in total

Review 1.  Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.

Authors:  Fabrício F T Barros; Desmond G Powe; Ian O Ellis; Andrew R Green
Journal:  Histopathology       Date:  2010-04       Impact factor: 5.087

2.  Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer.

Authors:  Hong Suk Song; Young Rok Do; In Ho Kim; Soo Sang Sohn; Kun Young Kwon
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

Review 3.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

Review 4.  HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.

Authors:  David G Hicks; Christa Whitney-Miller
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-12

5.  Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.

Authors:  J Lee; T Lim; J E Uhm; K W Park; S H Park; S C Lee; J O Park; Y S Park; H Y Lim; T S Sohn; J H Noh; J S Heo; C K Park; S Kim; W K Kang
Journal:  Ann Oncol       Date:  2007-02-13       Impact factor: 32.976

6.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

Review 7.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.

Authors:  K Sakai; S Mori; T Kawamoto; S Taniguchi; O Kobori; Y Morioka; T Kuroki; K Kano
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

Review 10.  The role of S-1 in the treatment of gastric cancer.

Authors:  T Kubota
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640
View more
  18 in total

Review 1.  Targeted therapy for advanced gastric cancer: A review of current status and future prospects.

Authors:  Ozkan Kanat; Bert O'Neil; Safi Shahda
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

2.  Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma.

Authors:  Li Zou; Jun Qian
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

3.  RNAi-mediated silencing of NOX4 inhibited the invasion of gastric cancer cells through JAK2/STAT3 signaling.

Authors:  Xiang Gao; Jingping Sun; Chunyu Huang; Xiaohua Hu; Ning Jiang; Chenqi Lu
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

Review 4.  The BRAF activated non-coding RNA: A pivotal long non-coding RNA in human malignancies.

Authors:  Xiu-Fen Liu; Ji-Long Hao; Tian Xie; Om Prakash Pant; Cheng-Bo Lu; Cheng-Wei Lu; Dan-Dan Zhou
Journal:  Cell Prolif       Date:  2018-02-27       Impact factor: 6.831

5.  Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis.

Authors:  Claus W Schildberg; Thomas Weidinger; Werner Hohenberger; Axel Wein; Melanie Langheinrich; Markus Neurath; Frank Boxberger
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

Review 6.  Long non-coding RNA PVT1: Emerging biomarker in digestive system cancer.

Authors:  Dan-Dan Zhou; Xiu-Fen Liu; Cheng-Wei Lu; Om Prakash Pant; Xiao-Dong Liu
Journal:  Cell Prolif       Date:  2017-10-12       Impact factor: 6.831

Review 7.  Gastric cancer: current and evolving treatment landscape.

Authors:  Weijing Sun; Li Yan
Journal:  Chin J Cancer       Date:  2016-08-31

8.  Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.

Authors:  Bai-Hua Luo; Feng Xiong; Jun-Pu Wang; Jing-He Li; Ming Zhong; Qin-Lai Liu; Geng-Qiu Luo; Xiao-Jing Yang; Ni Xiao; Bin Xie; Heng Xiao; Rui-Jie Liu; Chang-Sheng Dong; Kuan-Song Wang; Ji-Fang Wen
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

9.  Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.

Authors:  Tao Du; Ying Qu; Jianfang Li; Hao Li; Liping Su; Quan Zhou; Min Yan; Chen Li; Zhenggang Zhu; Bingya Liu
Journal:  Mol Cancer       Date:  2014-05-04       Impact factor: 27.401

10.  Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer.

Authors:  Shen Li; Ziyu Li; Ting Guo; Xiao-Fang Xing; Xiaojing Cheng; Hong Du; Xian-Zi Wen; Jia-Fu Ji
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.